M. J. D. M. Luken

Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.

N. Tunariu, Juanita Lopez, U. Banerji, 2016 .

First-in-human, phase I, dose-escalation study of selective PI3K{alpha} isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.

J. Nemunaitis, D. Juric, J. Bono, 2015 .

Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents

Y. Bang, A. Patnaik, J. Bendell, 2018, Clinical Trials.

AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer an

S. Barry, G. Shapiro, J. Bono, 2016 .

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

N. Tunariu, U. Banerji, T. Yap, 2015 .

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

U. Banerji, T. Yap, M. O'Brien, 2017, European journal of cancer.